Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort StudyThomas Benfield, Hanne Rolighed Christensen, Jens Lundgren et al.|Clinical Infectious Diseases|2021Cited by 93
First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort studyJon Gitz Holler, Zitta Barrella Harboe, Robert Eriksson et al.|BMC Infectious Diseases|2021Cited by 49
Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and InfectionAnna Karina Juhl, S. F. Caspersen, Lisa Loksø Dietz et al.|The Journal of Infectious Diseases|2024Cited by 10
Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasoneCæcilie Leding, Thomas Benfield, Jacob Bodilsen et al.|Scandinavian Journal of Infectious Diseases|2023Cited by 7
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19Tomas Ø. Jensen, Mark D. Miller, Greg Grandits et al.|The Journal of Infectious Diseases|2023Cited by 4